FDA Inspection 1117664 — Pfizer Boulder
The FDA completed an inspection of Pfizer Boulder on December 20, 2019 in Boulder, CO. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 20, 2019
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Boulder, CO (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)